Assessing Illumina (ILMN) Valuation After New Labcorp And Preventive Genomics Alliances

Why Illumina’s new alliances matter for stock watchers

Illumina (ILMN) has just expanded its collaboration with Labcorp and entered a new consortium with Veritas Genetics and Fuze Health, putting next generation sequencing at the center of both cancer care and preventive genomics.

See our latest analysis for Illumina.

These alliances have arrived while Illumina’s share price has seen a 5.2% 30 day share price return and a 3.8% 7 day share price return. However, the 1 year total shareholder return of 40.6% contrasts with weaker 3 and 5 year total shareholder returns, suggesting recent momentum has picked up after a tougher period.

If you are comparing Illumina with other genomics and health focused names, this is a good moment to widen the search using our healthcare focused AI stock ideas through the 36 healthcare AI stocks.

With Illumina trading at $123.79 and sitting at a discount to both analyst targets and one intrinsic value estimate, the real question is whether recent alliances leave upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 9% Undervalued

Illumina’s fair value in the most followed narrative sits at $136.05 versus a last close of $123.79, putting that story on the optimistic side of current pricing.

Strong and resilient growth in clinical applications, especially oncology, genetic disease testing, and reproductive health, continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility. Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.

Read the complete narrative.

Curious what has to happen between now and 2028 for that $136.05 fair value to stack up? The narrative leans heavily on steady revenue expansion, a reset in margins, and a future earnings multiple that sits below many peers but above today’s implied level. The mix between clinical demand, share count changes, and required return assumptions does a lot of the heavy lifting in this model.

Result: Fair Value of $136.05 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on China risks and tighter research budgets not worsening, as both could pressure Illumina’s revenue mix and the multiple in that story.

Find out about the key risks to this Illumina narrative.

Next Steps

With sentiment clearly mixed, both around recent alliances and valuation, it makes sense to move quickly and test the assumptions against your own expectations using the 3 key rewards and 1 important warning sign.

Ready for more investment ideas?

Do not stop with a single company when there are entire lists of potential ideas already filtered for you. Let the data do the heavy lifting and keep your watchlist fresh.

• Target quality at a discount by scanning our set of 55 high quality undervalued stocks that pair lower prices with stronger fundamentals than many broad benchmarks.
• Prioritize resilience by reviewing the 74 resilient stocks with low risk scores built around companies with lower overall risk scores than the wider market.
• Spot early opportunities by checking the screener containing 26 high quality undiscovered gems that highlight solid businesses investors may be overlooking today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com